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Arthur Michael Feldman MD, PhD has been named the Magee
Professor and Chairman of the Department of Medicine. He
joins Jefferson on July 1 from the University of Pittsburgh,
where he was the Harry S. Tack Professor of Medicine, Chief of
Cardiology at the University of Pittsburgh School of Medicine,
and Director of
the
Cardiovascular
Institute of
UPMC Health
System.
"Arthur
Feldman’s proven
leadership ability
and boundless
energy, coupled
with his superior
reputation as a
clinician scientist,
will be assets to
Jefferson as we
embrace the
challenges of the
new
millennium," said
Thomas J. Nasca
’75, Dean of the Medical College.
Dr. Feldman received a bachelor’s degree in 1970 from
Gettysburg College, a doctor of philosophy degree in 1974
from the University of Maryland, College Park, and a doctor of
medicine degree in 1981 from Louisiana State University
School of Medicine in Shreveport. 
He was an intern, resident and cardiology fellow at the Johns
Hopkins Hospital in Baltimore. At Hopkins, he rose to become
director of the Heart Failure Research Program in the Division
of Cardiology and director of the Belfer Laboratory for the
Molecular Biology of Heart Failure at the Johns Hopkins
University School of Medicine. He joined the UPMC Health
System in 1994.
Dr. Feldman has a longstanding interest in both the molecular
and clinical aspects of congestive heart failure. At the
molecular level, he has been attempting to identify genes that
serve as markers for CHF, while at the clinical level, he has
studied the use of genetically engineered proteins to treat the
disease. Among many advances in his research, he has
generated transgenic mice that overexpress TNF and develop
congestive heart failure.
4    J E F F E R S O N M e d i c a l  C o l l e g e  A l u m n i  B u l l e t i n J u n e  2 0 0 2
Dr. Feldman is currently principal investigator for several
National Institutes of Health grants that support these
interests. At the clinical level, he chairs the Steering
Committee of the PEECH trial evaluating the efficacy of
enhanced external counterpulsation, the EMOTE trial
assessing the benefits of inotropic agents in the treatment of
heart failure, and serves as co-chair of the COMPANION trial,
a multi-center study in 2200 patients evaluating the use of bi-
ventricular pacing for the treatment of heart failure.
Dr. Feldman is a fellow of the American Heart Association and
of the American College of Cardiology. He is President of the
Association of Professors of Cardiology for 2002-2003, is the
immediate past President of the Heart Failure Society of
America and is a councilor of the Association of University
Cardiologists. He serves on numerous American College of
Cardiology and American Heart Association committees. He
also co-chairs the American Heart Association Task Force on
Translational Medicine and Functional Genomics. 
He currently serves on the editorial boards of the Journal of the
American College of Cardiology, Journal of Molecular and
Cellular Cardiology, Heart Failure Review, Journal of
Cardiovascular Pharmacology and Therapeutics, Journal of
Cardiac Failure and Heart Failure. He is senior editor of
Congestive Heart Failure.
Dr. Feldman is the author of numerous articles and book
chapters on heart failure and related topics. He also serves on
the Board of Trustees of Gettysburg College.
Noted Cardiologist Arthur Feldman Is
Named Chairman of the Department of Medicine
N E W  A P P O I N T M E N T S
Merli Named Senior Associate Dean
Geno Merli ’75, who has been
widely admired for his contribu-
tions to the Department of
Medicine during his term as
interim Chair, will take on new
responsibilities as Vice Chair for
Clinical Affairs in the Department
of Medicine and Senior Associate
Dean for Continuing Medical
Education at Jefferson Medical
College. He will also resume his
previous role as the Ludwig Kind
Professor and Director of the Division of General Internal
Medicine at Jefferson Medical College and Thomas Jefferson
University Hospital.
5Clara A. Callahan
PD’82 has a new post
as Vice Dean for
Academic Affairs at
Jefferson Medical
College.
Dr. Callahan, a
Clinical Associate
Professor of
Pediatrics, previously
served as Senior
Associate Dean for
Admissions and
Student Life and the
Lillian H. Brent Dean
for Students.
She has distinguished herself during the past 20 years at
Jefferson, focusing on improving medical school and
postgraduate training. She has also endeared herself to the
medical students by taking a personal interest in their
progress. The 1992 senior class presented a portrait of Dr.
Callahan to the university.
Dr. Callahan completed the Culpepper Fellowship in
Ambulatory Pediatrics at Thomas Jefferson University
Hospital and has been on the Jefferson faculty since 1982. She
joined the dean's staff in 1987.
Weigel Will Be Vice Chair of Surgery 
and Director of the New Breast Center
Ronald J. Weigel MD, PhD has been recruited as Vice Chair of
Surgery and Director of the newly established Breast Center at
Thomas Jefferson University Hospital.
Dr. Weigel, who previously served as Associate Professor of
Surgery at the Stanford University School of Medicine, was
also named the first Francis E. Rosato Professor of Surgical
Oncology, and Chief of Surgical Oncology at Jefferson’s
Kimmel Cancer Center.
"Dr. Weigel will help develop a strategic plan for breast care
at Jefferson, as well as enhancing the research and academic
Callahan Appointed 
Vice Dean for Academic Affairs
programs in the Department of Surgery," said Donald Dafoe
MD, the Samuel D. Gross Professor and Chair of the
Department. “Having Dr. Weigel here will have a tremendous
impact on Jefferson’s continued ability to provide the best
care and treatment for breast cancer and other breast
diseases.”  
Dr. Weigel’s research has focused on hormone responsive
diseases. Nationally recognized for his expertise in thyroid
and parathyroid surgery, Dr. Weigel's research efforts have
made major advances in understanding how estrogen affects
breast cancer growth. Dr. Weigel said his goal for the Breast
Center is to have both clinical research and care programs
located within one facility. As part of that goal, Dr. Weigel
said he hopes to see additional
radiation and medical oncologists
recruited for the Breast Center.
“We want to make it easier for
patients to obtain the best care
and treatment possible,” Dr.
Weigel said.
As a successful recipient of
National Institutes of Health
funding for the last 10 years, Dr.
Weigel has conducted research
utilizing breast cancer as a model
for the study of hormone
responsive tumors. The American College of Surgeons has
recognized his outstanding contributions to surgical research
by presenting Dr. Weigel with the George H. Clowes, Jr.
Memorial Research Center Development Award for the past
five years.
Dr. Weigel has served as a research fellow for the American
Surgical Association and has been an Associate Editor of the
Journal of Surgical Research and a member of the editorial
board of the Annals of Surgical Oncology.
Dr. Weigel completed his surgical training at Duke University
Medical Center and also completed a postdoctoral fellowship
in Microbiology and Immunology at Duke. In 1986, Dr.
Weigel received both a doctor of medicine degree and a
doctor of philosophy degree in molecular biophysics and
biochemistry from Yale University. He earned a bachelor of
science degree and a master of science degree in chemical
engineering from the Massachusetts Institute of
Technology.
G I F T  O F  H E A L T H
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Herbert Kean OTO’60, Clinical Professor of Otolaryngology, has
made a commitment to Jefferson Medical College to establish an
endowed chair in the Department of Otolaryngology-Head and Neck
Surgery. The new chair, to be known as The Herbert Kean MD Chair
in Otolaryngology, will support
the activities of the chairman of
the department. 
Recently retired, Dr. Kean’s
association with Jefferson is
now in its fifth decade. After
completing his postgraduate
training in otolaryngology and
plastic facial surgery at
Jefferson, he returned to
become a member of the faculty
in 1969. He performed the first
outpatient procedure at the
Jefferson Surgical Center in 1986, as well as the 50,000th outpatient
procedure in 1998.  
“This very generous gift is a demonstration of Herb’s longstanding
commitment to the continuing growth and vitality of the
department,” says William M. Keane MD, Professor and Chairman of
the Department of Otolaryngology-Head and Neck Surgery. “As an
outstanding clinician and educator he has touched the lives of
hundreds of resident physicians. His endowing of a chair is a manifes-
tation of his dedication to our department and guarantees that his
legacy of superb patient care coupled with education and research
will endure.”  
Dr. Kean hopes his contribution will set an example for others. “I had
two purposes in making this gift, which is for the Department of
Otolaryngology,” he explains.
“First, it was a way for me to repay a debt to Jefferson for the training
that led to success in my specialty. I was a resident at Jeff, and I got a
wonderful education in my residency.”
“My second goal in doing this was to make life easier for the chair of
the department. The current chair is Bill Keane, of course. Bill is an
excellent chair, probably the best in the country. I’m especially close
to him because his goals for the future of the department are so
similar to my own.” 
Expressing appreciation for this funding of a new professorship,
Thomas J. Nasca ’75, Dean of Jefferson Medical College, said, “The
establishment of endowed chairs is essential to the future of JMC, and
it is especially significant when a chair is funded by one of our
faculty. In fact, this is one of the few chairs – perhaps even the first –
to be funded by a JMC faculty member during his or her lifetime.
Herb Kean’s gift will strengthen our already outstanding department
and chair.”
New studies in mice indicate low doses of chemotherapy drugs given
more frequently than usual and in tinier doses may target the process by
which a new blood supply is created feeding tumor growth, called
angiogenesis. 
Most cancer therapies are traditionally used in the highest possible
doses, explains Adam Dicker MD, PhD, Associate Professor of Radiation
Oncology. But anti-angiogenesis drugs have caused people to rethink
chemotherapy. Dr. Dicker and others have previously published research
showing that using chemotherapy in lower than usual doses can have
antiangiogenic effects in the laboratory.
In a recent study, Dr. Dicker, former graduate student Torian
Williams, and their co-workers at Jefferson and GlaxoSmithKline in
King of Prussia, Pennsylvania, filled osmotic pumps the size of pencil
erasers with low concentrations of paclitaxel (Taxol) and docetaxel
(Taxotere). Such pumps allow drugs to diffuse continuously slowly. They
Jefferson Receives $1.5 Million to Establish Scholarship
Ruth N. Cooper appreciated the dedication of her physicians, Leonard S.
Davitch ’43, Honorary Clinical Assistant Professor of Medicine, and
David L. Paskin ’64, Professor of Surgery, Senior Associate Dean for
Graduate Medical Education and Associate Dean for Affiliations. Ms.
Cooper also appreciated the importance of the education that prepared
physicians for their profession.
Now, Jefferson and its students are beneficiaries of her gratitude.
Following her death in 2001, her estate provided $1.5 million (with
additional funds anticipated) to create the Ruth N. Cooper Scholarship
Fund at Jefferson, and also bequeathed $5,000 to the Department of
Internal Medicine in honor of Dr. Davitch.
"Tuition fees cover only part of the actual costs of medical education, and
our students and their families often have limited resources," said Susan
Batchelor, University Director of Financial Aid. "Private scholarships
established by friends such as Ms. Cooper are vital to our financial aid
program, and enable new generations of students to benefit from the
excellence of a Jefferson education. We are very grateful for her kind
generosity."
Ms. Cooper, one of five children of the late Elsie and Maurice Cooper, is
survived by her sisters, Sally Bleznak and Joan Sall, and her brother,
Norton Cooper. The Ruth N. Cooper Scholarship is the second award at
Jefferson that honors a member of the Cooper family. The Jerome J.
Cooper Scholarship was established in memory of Ms. Cooper’s other
brother by their mother, Elsie, and Jerome Cooper’s widow, Delphine
Cooper Chomitz.
Scholarship donors derive satisfaction from honoring their loved ones
while helping Jefferson to prepare future generations of physicians. To
learn how you can create such a legacy, please call Fritz Ruccius or Lisa
Watson Repko of Jefferson Trusts and Estates, toll free, at 1-877-JEFF
GIFT (1-877-533-3443). You may also e-mail your questions to
jeff.trust@mail.tju.edu or visit the Jefferson Trusts and Estates website at
http://jeffline.tju.edu/tjuweb/tju/jeffgiving/plangiv.htm
Herbert Kean Endows Chair
in Otolaryngology
Dr. Kean and his wife, 
the Hon. Joyce Kean
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Steven Farber PhD, Assistant Professor of Microbiology and
Immunology, and Director of the Kimmel Cancer Center Zebrafish
Facility, is a young investigator who gives two reasons for his
fascination with zebrafish. 
A recent Pew Scholars Program
recipient, Farber uses them in
his innovative genetic research.
So named because of their
zebra-like stripes, these are tiny
fish, growing to no longer than
one and one-quarter inches.
Research scientists like Farber
think these animals are key to
understanding and treating
many diseases affecting humans
because their genes are nearly
identical to human genes.
Abundant and accessible in the
laboratory, they develop rapidly
following birth, growing in less
than a week from a single cell to
a swimming larva with all
organs complete. 
However, the magic that makes the zebrafish unique for research
purposes is that, during their first week of existence, their bodies are
literally transparent, allowing scientists to view their bodily processes
using modern microscope technology. More importantly for
scientists, the zebrafish genome can be mutated readily. Dr. Farber
explains that with much of the human genome sequenced now,
zebrafish provide scientists with an excellent model to study the
function of many human genes, and to apply this new information to
human diseases.
Zebrafish: A Potential 
Community Outreach Program
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Dr. Farber’s second reason to be excited about zebrafish is their value
for instilling a love of science in young children because, as Dr.
Farber knows well, kids love zebrafish. Currently, he arranges and
conducts tours of the Jefferson facility for young children on a regular
basis, letting them peer at the fish and their magic transparency
through microscopes. His ultimate goal, however, is to be able to take
the creatures to the children by touring schools in Pennsylvania, New
Jersey, and Delaware for the purpose of instilling in children a love
for science, and hoping this exposure will lead to productive careers
in science for some of these children. 
As he points out, this initiative is a superb outreach opportunity for
Jefferson. As with most similar initiatives, the immediate problem for
Dr. Farber is to get the $60,000 seed money needed to start the
program. Both the National Science Foundation and the National
Institutes of Health have expressed interest in helping support this
innovative curriculum once it begins and shows promise of becoming
continually operative. The $60,000 in seed money is needed to begin
the effort, and will allow the hiring of a helper, the purchase of two
microscopes for the children to use, and travel expenses for taking
the zebrafish exhibit to the schools. Once the initiative is on firm
footing, Dr. Farber will seek a more permanent source of funding
from either the National Science Foundation or the National
Institutes of Health. 
This unique initiative to interest young children in science offers a
great opportunity for one or a group of Jefferson alumni to contribute
the seed money to start this project which promises great rewards for
children. Dr. Farber can be reached at 215-503-2472, or Farber
@lacjc.tju.edu, or in care of the Department of Microbiology and
Immunology, Jefferson Medical College.
I N V E S T I G A T I O N S
A group of students visits Dr. Farber’s lab at Jefferson from Imani
Education Circle Charter School in the Germantown section of
Philadelphia. At rear is postgraduate fellow Matthew Pearson PhD.
placed the pumps in mice in which human choriocarcinoma – which
is a very vascular tumor – had been implanted. The pumps slowly
released low doses of the drugs. They found the tumors became
smaller because the drugs inhibited the growth of endothelial cells,
which are key to the development of new blood vessels. 
When the scientists sectioned the tissue and looked at the blood
vessels, they found fewer blood vessels in the tumors that were treated
with drugs. They also saw no toxic effects in the animals.
“These results become important,” Dr. Dicker says, “because
eventually there will be oral versions of these drugs that are currently
given intravenously. It suggests that chronic, low dose concentrations
of drug for patients will be effective in treating cancer. Companies
are planning to come out with oral versions.”
Dr. Dicker and his coworkers plan to expand the work to other
cancerous tumors, including breast, prostate and brain tumors.
Effects

























